Author

T. S. Dexheimer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

R. R. Neubig· 3 shared S. A. Misek· 3 shared E. M. Lisabeth· 2 shared K. M. Appleton· 2 shared S. D. Larsen· 2 shared B. R. Martin· 1 shared C. C. Palsuledesai· 1 shared D. A. Fox· 1 shared

Activity by Year

2018-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. R. Neubig

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivSep 19, 2019

Inhibition of the Myocardin-Related Transcription Factor pathway increases efficacy of Trametinib in NRAS-mutant melanoma cell lines

K. M. Appleton, C. C. Palsuledesai, S. A. Misek…·R. R. Neubig

This study shows that inhibiting the Rho/MRTF pathway with CCG-222740 enhances trametinib's effectiveness in NRAS-mutant melanoma cell lines by reducing cell viability and clonogenicity.

DOI 10.3390/cancers13092012

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMar 31, 2019

Rho-mediated gene transcription promotes BRAF inhibitor resistance in de-differentiated melanoma cells

S. A. Misek, K. M. Appleton, T. S. Dexheimer…·R. R. Neubig

This study identifies RhoA-mediated gene transcription as a mechanism of BRAF inhibitor resistance in melanoma, showing that targeting this pathway can re-sensitize resistant cells to vemurafenib.

DOI 10.1101/381806

humanbulk RNA-seq

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivOct 31, 2018

Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Anti-Fibrotic and Anti-Metastatic Compounds

E. M. Lisabeth, D. Kahl, I. Gopallawa…·R. R. Neubig

This study identifies pirin as the molecular target of the CCG-1423/CCG-203971 compounds, showing its role in modulating MRTF-dependent gene expression and fibrosis.

DOI 10.1021/acsptsci.8b00048

humanproteomics

𝕏 PostBluesky